RESEARCH AND ARTS

ŠIFRA PROJEKTA NRP

5R01AG077725-04

ZAČETEK PROJEKTA

1. 11. 2024

KONEC PROJEKTA

31. 5. 2027

FINANCER

National Institutes of Health (NIH)

VREDNOST

2,126.586,78 EUR

SREDSTVA PEDAGOŠKE FAKULTETE UNIVERZE V MARIBORU

70.894,13 EUR

NOSILEC

Northeastern University, Boston

SODELUJOČE ORGANIZACIJE

OHSU

SODELUJOČI NA UM PEF

doc. dr. Maruša Laure

DESCRIPTION

The goal of this clinical trial is to learn how Auditory Training (AT) may help people better understand speech in noisy environments. As people get older, it becomes harder for them to hear speech clearly when there is background noise. This can be frustrating, and it can affect their independence and quality of life. AT is often used to support people with and without hearing loss, especially when a person is not a good candidate for a hearing aid or when amplification from a hearing aid does not improve performance.

We want to gather reliable data to understand how AT works and what affects its success.

The main questions the trial aims to answer are:

• How do different types of sounds influence the effectiveness of auditory training?
• Which auditory training approaches are most successful in improving speech understanding?
• How do personal traits impact the results of auditory training?

We will study a large and diverse group of 1,260 participants, including both young and older adults, to evaluate various auditory training approaches.

Participants will:

• Take part in auditory training sessions that include different types of auditory tasks.
• Complete tests that measure how well they understand speech in both quiet and noisy settings.
• Complete surveys on personal data like demographics, hearing challenges and other factors to help researchers understand what might influence training results.

We will measure and compare the results of these approaches to find out which ones are most effective. This could help people who are at risk of cognitive decline, like those at risk for Alzheimer’s disease.

The project R01AG077725 is financed by the National Institutes of Health (NIH).